Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 53.85

-4.5%

Jan 9 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (10805)	3/4/2004 1:20:35 PM
From: rkrw	Read Replies (4) of 52153

The anti-emetic took everyone by surprise. Except maybe Peter! I thought it could be their sleeper product but never acted on it. What an inlicensing! Very similar to ceph's modafanil inlicensing. Took quite a while before people realized it was mogn's drug to watch and not the cancer drug. mogn sect members probably now claim they saw it coming all along. Your assessment of mogn was right on years ago and as far as the cancer drug, still right on.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next